ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 1, 2005, Pages

  Kataja, V V ^a,c   Bergh, J ^b,c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ESMO Guidelines Task Force   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYPROTERONE ACETATE; DOCETAXEL; ESTRAMUSTINE; FLUTAMIDE; GESTAGEN; GONADORELIN DERIVATIVE; MITOXANTRONE; NILUTAMIDE; OPIATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; EUROPEAN UNION; FOLLOW UP; GYNECOMASTIA; HUMAN; MALE; MEDICAL SOCIETY; NEEDLE BIOPSY; ORCHIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 21044444047     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi826     Document Type: Article

References (15)

1. Catalona WJ, Richiek JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6639 men. J Urol 1994; 151: 1283-1290.
2. Kramer BS, Gohagan JK, Prorok PC. Clinical Oncology Update: Prostate Cancer. Is Screening for Prostate Cancer the Current Gold Standard? - "No". Eur J Cancer 1997; 33: 348-353.
3. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151: 1571-1574.
4. Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-712.
5. Lu Yao GL, Yao S-L. Population based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906-910.
6. Robinson MR, Smith PH, Richards B et al. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30 805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995; 28: 273-283.
7. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
8. Boccon-Gibod L. Monitoring and treating the patient after radical treatment of localized prostatic cancer. Eur Urol 1994; 20: 154-159.
9. Zagars GK. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am 1993; 20: 737-747.
10. Lawton CA, Winter K, Murray K et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946.
11. Pilepich MV, Winter K, John MJ et al. Phase III radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjunct to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252.
12. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchfull waiting in early prostate cancer. N Engl J Med 2002; 347: 781-789.
13. Small EJ, Halabi S, Dawson NA. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22: 1025-1033.
14. Tannoc IF, de Witt R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
15. Petrylak DP, Tangen C, Hussain M et al. Docetaxel and estramustine compared with mitoxantrone ans prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.